drugset / Trial / NCT05247957
NKG2D CAR-NK Cell Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia
NaSingle-groupOpen-labelTreatment
Summary
This trial will explore the maximum tolerated dose of cord blood NKG2D CAR-NK in the treatment of recurrent refractory acute myeloid leukemia in a dose-escalation manner, and observe its clinical safety and efficacy.
Timeline
- Start
- 2021-10-13
- Primary completion
- 2022-12-12
- Completion
- 2022-12-20
Outcome
Outcome not reported
Stopped: “end”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CAR-NK cells | Cell therapy | 2 cells/kg | — |
| Subject | CAR-NK cells | Cell therapy | 6 cells/kg | — |
| Subject | CAR-NK cells | Cell therapy | 18 cells/kg | — |
Indications
No indication recorded.